Is MindMed (MNMD) Stock the Next Big Short Squeeze?
- MindMed(MNMD) briefly doubled overnight on rumors of a short squeeze.
- The company is testing LSD to treat symptoms of ADHD, anxiety and other conditions.
- The drug is still in its Phase 2 study and a long way from the market.
Source: Shutterstock
Penny stockMind Medicine(NASDAQ:MNMD) stock nearly doubled overnight on rumors of a short squeeze.
Shares that opened at 68 cents early on Aug. 17 were trading at $1.16 before the market opened on Aug. 18, after trading as high as $1.40 earlier in the morning.
The move comes as the company prepares for a1-for-15 reverse stock split. After the split, there will be 28.4 million shares outstanding.
MNMD Stock: Behind the News
MindMedis researching the use of psychedelics for treatment of anxiety, pain, substance abuse and autism. It has a pipeline of drug candidates, but none are on the market currently. The companylost $17 million in the second quarter, 4 cents a share. It had about $105 million in cash on the books at the end of the quarter.
The stock is being helped by a decision from Cantor Fitzgerald to launch coverage with a price target of$3 per sharepre-split. The decision was shared onReddit, where traders urged others to“bring it back up where it should be.”
The Cantor call is based on hope that MM-120, now in Phase 2 trials, could prove effective against ADHD and generalized anxiety. The drug is anLSD D-tartrate, a version of the 1960s psychedelic still listed as a Schedule 1 drug. The company is also studying LSD for cluster headaches and major depression.
While success would help a lot of people, there are no guarantees. A Phase 2 study will only show whether a treatment works. A Phase 3 study is still needed to show it’s bothsafe and more effectivethan standard treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
read
Yo